BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) - Analysts at HC Wainwright reduced their Q3 2025 earnings per share (EPS) estimates for shares of BioNTech in a report released on Wednesday, June 25th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($1.12) for the quarter, down from their previous forecast of ($1.10). HC Wainwright currently has a "Buy" rating and a $138.00 price objective on the stock. The consensus estimate for BioNTech's current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech's Q1 2026 earnings at ($2.24) EPS, Q2 2026 earnings at ($2.27) EPS and FY2026 earnings at ($4.32) EPS.
Several other equities research analysts have also issued reports on BNTX. BMO Capital Markets lifted their price target on BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 11th. Leerink Partners set a $112.00 price objective on BioNTech in a report on Monday, June 2nd. Wall Street Zen raised BioNTech from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th. Canaccord Genuity Group reiterated a "buy" rating and set a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. Finally, JPMorgan Chase & Co. decreased their price target on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research note on Thursday, May 22nd. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $137.86.
View Our Latest Research Report on BioNTech
BioNTech Stock Up 1.3%
Shares of NASDAQ:BNTX opened at $106.14 on Friday. The firm has a market capitalization of $25.51 billion, a PE ratio of -31.22 and a beta of 1.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.02 and a current ratio of 10.18. BioNTech has a 52-week low of $76.53 and a 52-week high of $131.49. The firm has a fifty day moving average of $102.63 and a 200 day moving average of $107.30.
Institutional Investors Weigh In On BioNTech
Several institutional investors have recently added to or reduced their stakes in the company. Banque Cantonale Vaudoise purchased a new stake in BioNTech in the 1st quarter worth approximately $36,000. Jones Financial Companies Lllp raised its holdings in shares of BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after acquiring an additional 246 shares in the last quarter. Banque Transatlantique SA purchased a new stake in BioNTech in the first quarter worth $80,000. Quintet Private Bank Europe S.A. lifted its stake in BioNTech by 823.5% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock worth $88,000 after acquiring an additional 700 shares during the period. Finally, Allianz SE bought a new stake in BioNTech in the fourth quarter valued at $90,000. Hedge funds and other institutional investors own 15.52% of the company's stock.
About BioNTech
(
Get Free Report)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioNTech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.
While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
